Skip to main content

Skadden, Arps, Slate, Meagher & Flom has advised Shanghai-based biopharmaceutical company JHBP (CY) Holdings, a holding company for Genor Biopharma,  on its HK $2.87 billion ($371 million) IPO in Hong Kong, with Kirkland & Ellis representing the joint sponsors and the underwriters.

Founded in 2007, Genor is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs The public offering was oversubscribed 1,247 times, making it one of the most sought-after biotech IPOs in Hong Kong this year.

The offering is part of a recent flurry of IPOs and secondary listings worth at least $4.5 billion currently being launched in Hong Kong, with Reuters reporting that 2020 is on track to be the second-busiest year for equity capital markets in the city. Recently, Chinese companies Yum China Holdings, Zai Lab and ZTO Express undertook successful secondary listings on HKEX while Ming Yuan Cloud Group went public in Hong Kong.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.